Physician profile
Jan L Pring
NPI 1205082088
$818.51
in general payments reported to CMS, 2019-2025
10 companies · $72.37 in 2025
The $72.37 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2021: $248 · 2024: $119 · 2025: $72.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $191.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $237.23 | 2021-2025 | Fasenra |
| Pulmonx Corporation | $132.28 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $123.11 | 2019 | |
| Genzyme Corporation | $120.75 | 2019 | |
| Veran Medical Technologies, INC. | $106.67 | 2019 | |
| United Therapeutics Corporation | $41.90 | 2021-2024 | Tyvaso |
| E.R. Squibb & Sons, L.L.C. | $16.22 | 2019 | |
| Glaxosmithkline, LLC. | $15.47 | 2024 | Trelegy Ellipta |
| Philips North America LLC | $13.08 | 2019 | |
| Abbott Laboratories | $11.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jan Pring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.